Affiliation:
1. Department of Otolaryngology and Head & Neck Surgery, Cigli Training and Research Hospital Bakircay University Faculty of Medicine Izmir Turkey
2. Department of Otolaryngology and Head & Neck Surgery, Izmir Bozyaka Training and Research Hospital University of Health Sciences Izmir Turkey
3. Department of Otolaryngology and Head & Neck Surgery Izmir Bayrakli City Hospital Izmir Turkey
Abstract
ObjectiveThis study aimed to compare the pharyngocutaneous fistula (PCF) between patients who underwent reconstruction using cervical fascia after total laryngectomy and those who did not and to investigate the factors affecting PCF rates.MethodsWe retrospectively compared 22 patients operated between February 2021 and March 2023 who received cervical fascia flap as the study group and 21 patients operated between January 2018 and March 2023 who did not receive fascia flap as the control group. The study included patients who underwent total laryngectomy for Stage 3 and 4 squamous cell laryngeal cancer.ResultsWe included 43 patients, with 22 (51.2%) and 21 patients (48.8%) in the study and control groups, respectively. The age and sex were not different between the two groups (p = 0.471, p = 0.176, respectively). The distribution of patients as per sex, smoking, alcohol use, chronic obstructive pulmonary disease, diabetes mellitus, coronary artery disease, and multiple comorbidities was similar in both groups (p > 0.05). PCF was observed in one patient (4.5%) and seven patients (33.3%) in the study and control groups, respectively. The PCF rate was significantly lower in the study group (p = 0.021). When the relationship between flap use and risk factors was compared by correlation analysis, a moderate negative relationship was found between flap use and PCF (p = 0.015, r = −0.370).ConclusionThe use of a cervical fascia flap is effective in reducing fistula rates after total laryngectomy. Its main advantages include being technically simpler than alternative techniques, locally available, cost‐effective.Level of EvidenceLevel 3 Laryngoscope, 2024